Infant Bacterial Therapeutics Management
Management criteria checks 2/4
Infant Bacterial Therapeutics' CEO is Staffan Stromberg, appointed in Jan 2013, has a tenure of 11.92 years. total yearly compensation is SEK5.33M, comprised of 57.9% salary and 42.1% bonuses, including company stock and options. directly owns 0.79% of the company’s shares, worth SEK5.99M. The average tenure of the management team and the board of directors is 1.6 years and 7.6 years respectively.
Key information
Staffan Stromberg
Chief executive officer
SEK 5.3m
Total compensation
CEO salary percentage | 57.9% |
CEO tenure | 11.9yrs |
CEO ownership | 0.8% |
Management average tenure | 1.6yrs |
Board average tenure | 7.6yrs |
Recent management updates
Recent updates
Will Infant Bacterial Therapeutics (STO:IBT B) Spend Its Cash Wisely?
Dec 05We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 02Infant Bacterial Therapeutics AB (publ)'s (STO:IBT B) CEO Compensation Is Looking A Bit Stretched At The Moment
May 02Infant Bacterial Therapeutics (STO:IBT B) Is In A Good Position To Deliver On Growth Plans
Apr 03Here's Why We're Not Too Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Situation
Sep 16We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
May 11We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
Sep 23We're Hopeful That Infant Bacterial Therapeutics (STO:IBT B) Will Use Its Cash Wisely
Apr 07We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Dec 15We Think Infant Bacterial Therapeutics (STO:IBT B) Can Afford To Drive Business Growth
Aug 25We're Not Very Worried About Infant Bacterial Therapeutics' (STO:IBT B) Cash Burn Rate
May 06Anthon Jahreskog Just Bought A Sprinkling of Shares In Infant Bacterial Therapeutics AB (publ) (STO:IBT B)
Feb 07CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -SEK 144m |
Jun 30 2024 | n/a | n/a | -SEK 142m |
Mar 31 2024 | n/a | n/a | -SEK 128m |
Dec 31 2023 | SEK 5m | SEK 3m | -SEK 123m |
Sep 30 2023 | n/a | n/a | -SEK 122m |
Jun 30 2023 | n/a | n/a | -SEK 99m |
Mar 31 2023 | n/a | n/a | -SEK 69m |
Dec 31 2022 | SEK 6m | SEK 3m | -SEK 65m |
Sep 30 2022 | n/a | n/a | -SEK 42m |
Jun 30 2022 | n/a | n/a | -SEK 34m |
Mar 31 2022 | n/a | n/a | -SEK 65m |
Dec 31 2021 | SEK 5m | SEK 3m | -SEK 45m |
Sep 30 2021 | n/a | n/a | -SEK 55m |
Jun 30 2021 | n/a | n/a | -SEK 74m |
Mar 31 2021 | n/a | n/a | -SEK 73m |
Dec 31 2020 | SEK 4m | SEK 2m | -SEK 72m |
Sep 30 2020 | n/a | n/a | -SEK 73m |
Jun 30 2020 | n/a | n/a | -SEK 65m |
Mar 31 2020 | n/a | n/a | -SEK 44m |
Dec 31 2019 | SEK 3m | SEK 2m | -SEK 46m |
Sep 30 2019 | n/a | n/a | -SEK 43m |
Jun 30 2019 | n/a | n/a | -SEK 40m |
Mar 31 2019 | n/a | n/a | -SEK 32m |
Dec 31 2018 | SEK 3m | SEK 2m | -SEK 41m |
Sep 30 2018 | n/a | n/a | -SEK 26m |
Jun 30 2018 | n/a | n/a | -SEK 22m |
Mar 31 2018 | n/a | n/a | -SEK 37m |
Dec 31 2017 | SEK 3m | SEK 1m | -SEK 36m |
Compensation vs Market: Staffan's total compensation ($USD480.69K) is above average for companies of similar size in the Swedish market ($USD231.35K).
Compensation vs Earnings: Staffan's compensation has been consistent with company performance over the past year.
CEO
Staffan Stromberg (57 yo)
11.9yrs
Tenure
SEK 5,327,000
Compensation
Mr. Staffan Stromberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Stromberg served as Director at Genetic Analysis AS since October 28, 2020 u...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | 11.9yrs | SEK 5.33m | 0.79% SEK 6.0m | |
Chief Financial Officer | 2.3yrs | no data | 0.035% SEK 263.5k | |
Chief Operating Officer | 6.9yrs | SEK 500.00k | 0.083% SEK 626.8k | |
Chief Scientific Officer | less than a year | no data | no data | |
Head of Medical Affairs | less than a year | no data | no data | |
Chief Medical Officer | less than a year | no data | no data |
1.6yrs
Average Tenure
57yo
Average Age
Experienced Management: IBT B's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chairman | 13.9yrs | SEK 727.00k | no data | |
Independent Director | 9.3yrs | SEK 153.00k | 0.039% SEK 295.9k | |
Independent Director | 7.6yrs | SEK 153.00k | 0.0042% SEK 31.4k | |
Independent Director | 6.6yrs | SEK 153.00k | 0.00074% SEK 5.6k | |
Independent Director | 7.6yrs | SEK 193.00k | 0.18% SEK 1.4m |
7.6yrs
Average Tenure
58yo
Average Age
Experienced Board: IBT B's board of directors are considered experienced (7.6 years average tenure).
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 16:01 |
End of Day Share Price | 2024/12/23 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Infant Bacterial Therapeutics AB (publ) is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Taylor Feehley | Chardan Capital Markets, LLC |